Bunting Michael, Chan Warren, Brand Alison, Blomfield Penelope
Department of Obstetrics and Gynaecology, The Royal Hobart Hospital, Hobart, Tasmania.
Aust N Z J Obstet Gynaecol. 2009 Dec;49(6):667-71. doi: 10.1111/j.1479-828X.2009.01080.x.
The administration of intraperitoneal (IP) chemotherapy as first-line adjuvant treatment for women with optimally debulked advanced ovarian malignancy results in improved median and overall survival when compared with intravenous (IV) chemotherapy. However, the number of adverse events and toxicities are increased in patients treated with IP chemotherapy. In addition, the administration of IP chemotherapy is technically more challenging and the schedule is more demanding in terms of time and resources.
We report on our initial experience with the administration of IP chemotherapy at two gynaecological oncology units in Australia.
We collected retrospective data from a series of 23 women undergoing IP chemotherapy as adjuvant treatment for advanced ovarian cancer. In addition to standard (Common Terminology Criteria for Adverse Events v3.0, CTCAE) toxicity data, we collected technical data specific to the administration of IP chemotherapy.
The average number of IP chemotherapy cycles received was 4.3. Forty-three per cent of patients received all six planned IP chemotherapy cycles. Thirty-nine per cent of patients discontinued their IP treatment. Of those, 22% were discontinued because of drug-related toxicities and the remaining 17% experienced a port complication or toxicity directly related to the route of administration.
This study demonstrates the feasibility and practicality of and lessons learned from initial experiences with IP chemotherapy for ovarian cancer in Australia.
对于接受了理想肿瘤细胞减灭术的晚期卵巢恶性肿瘤女性患者，与静脉化疗相比，腹腔内（IP）化疗作为一线辅助治疗可改善中位生存期和总生存期。然而，接受IP化疗的患者不良事件和毒性反应数量会增加。此外，IP化疗的实施在技术上更具挑战性，且在时间和资源方面对治疗计划要求更高。
我们报告在澳大利亚两个妇科肿瘤治疗中心进行IP化疗的初步经验。
我们收集了23例接受IP化疗作为晚期卵巢癌辅助治疗患者的回顾性数据。除了标准（不良事件通用术语标准第3.0版，CTCAE）毒性数据外，我们还收集了IP化疗实施的特定技术数据。
接受IP化疗的平均周期数为4.3个。43%的患者接受了全部六个计划的IP化疗周期。39%的患者停止了IP治疗。其中，22%因药物相关毒性而停药，其余17%出现了与端口相关的并发症或与给药途径直接相关的毒性反应。
本研究证明了澳大利亚IP化疗治疗卵巢癌初步经验的可行性、实用性及从中吸取的教训。
